MaxCyte, Inc. Increase (Decrease) in Deferred Revenue
MaxCyte, Inc. (MXCT) reported Increase (Decrease) in Deferred Revenue of -$1.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-13
- MaxCyte, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$808.00K.
- MaxCyte, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$327.00K.
- MaxCyte, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$1.60M.
- MaxCyte, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $2.75M, a 16.26% decline year-over-year.
- MaxCyte, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$1.68M, a 1021.98% decline from fiscal 2024.
- MaxCyte, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $182.00K.
- MaxCyte, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$1.64M.
- MaxCyte, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$34.00K, a 101.79% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$808.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.14M 10-Q · filed 2026-08-13 | -$2.73M derived: sum of 3 quarters · filed 2026-08-13 | $18.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$327.00K 10-Q · filed 2026-05-13 | -$1.93M derived: sum of 2 quarters · filed 2026-05-13 | $826.00K derived: sum of 3 quarters · filed 2026-05-13 | -$679.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.15M derived: sum of 2 quarters · filed 2026-03-25 | -$352.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.68M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2026-08-13 | -$80.00K 10-Q · filed 2025-11-13 | -$1.48M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.83M 10-Q · filed 2026-08-13 | -$4.23M derived: sum of 3 quarters · filed 2026-08-13 | -$948.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$1.33M 10-Q · filed 2026-05-13 | -$2.73M derived: sum of 2 quarters · filed 2026-05-13 | $557.00K derived: sum of 3 quarters · filed 2026-05-13 | -$551.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.88M derived: sum of 2 quarters · filed 2026-03-25 | $775.00K derived: sum of 3 quarters · filed 2026-03-25 | $182.00K 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.18M derived: sum of 2 quarters · filed 2025-11-13 | $1.58M 10-Q · filed 2025-11-13 | $1.07M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.70M 10-Q · filed 2025-08-06 | -$2.22M derived: sum of 3 quarters · filed 2025-08-06 | -$1.32M derived: sum of 4 quarters · filed 2025-08-06 | |||
| 2024-03-31 | -$593.00K 10-Q · filed 2025-05-08 | -$1.11M derived: sum of 2 quarters · filed 2025-05-08 | -$217.00K derived: sum of 3 quarters · filed 2025-05-08 | -$1.27M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | -$517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $376.00K derived: sum of 2 quarters · filed 2025-03-11 | -$681.00K derived: sum of 3 quarters · filed 2025-03-11 | -$1.64M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $893.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$164.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.13M 10-Q · filed 2024-11-06 | -$1.13M 10-Q · filed 2023-11-08 | -$706.00K derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.02M 10-Q · filed 2024-08-06 | -$1.60M derived: sum of 3 quarters · filed 2024-08-06 | -$2.62M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | -$963.00K 10-Q · filed 2024-05-07 | -$963.40K 10-Q · filed 2023-05-10 | -$542.00K derived: sum of 2 quarters · filed 2024-05-07 | -$1.56M derived: sum of 3 quarters · filed 2024-05-07 | -$1.08M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$597.80K derived: sum of 2 quarters · filed 2024-03-12 | -$118.90K derived: sum of 3 quarters · filed 2024-03-12 | -$34.00K 10-K · filed 2024-03-12 | -$34.20K 10-K · filed 2023-03-15 | ||
| 2022-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$539.90K derived: sum of 2 quarters · filed 2023-11-08 | -$455.00K 10-Q · filed 2023-11-08 | -$34.00K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $478.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $563.80K 10-Q · filed 2023-08-09 | $984.80K derived: sum of 3 quarters · filed 2023-08-09 | $555.80K derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $84.90K 10-Q · filed 2023-05-10 | $505.90K derived: sum of 2 quarters · filed 2023-05-10 | $76.90K derived: sum of 3 quarters · filed 2023-05-10 | $764.30K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$8.00K derived: sum of 2 quarters · filed 2023-03-15 | $679.40K derived: sum of 3 quarters · filed 2023-03-15 | $1.90M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $258.40K derived: sum of 2 quarters · filed 2022-11-09 | $1.48M 10-Q · filed 2022-11-09 | $1.67M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $687.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.91M 10-Q · filed 2022-08-10 | $2.10M derived: sum of 3 quarters · filed 2022-08-10 | $1.68M derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2021-03-31 | $1.22M 10-Q · filed 2022-05-09 | $1.41M derived: sum of 2 quarters · filed 2022-05-09 | $995.20K derived: sum of 3 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $188.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$229.20K derived: sum of 2 quarters · filed 2022-03-22 | $1.65M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | -$417.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.46M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $1.88M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $795.90K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |